Russia has now matured beyond being an emerging market and is now "a growing potential superpower", according to Synergy Research Group, which formed this conclusion after attending a conference.
The Russia-based contract research organisation (CRO) also believes that there is no competition between Russia, India and China for international clinical trials.
In addition the CRO claims that the clinical trial market has so far been unaffected by the economic downturn. Two reasons are cited for this: the length of the drug development cycle and the "elasticity of a medicine".
The CRO goes on to claim that Russia can benefit from the economic downturn by helping small to mid-sized companies cut development times and reach the market quicker.
Source: Pharma Update
